We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J to Gain Promising Autoimmune Disease Drug in $6.5 Billion Momenta Acquisition
J&J to Gain Promising Autoimmune Disease Drug in $6.5 Billion Momenta Acquisition
Johnson & Johnson (J&J) announced that it will acquire the autoimmune-focused biotech company Momenta Pharmaceuticals for $6.5 billion, expanding its holdings in the area of novel treatments for autoimmune diseases.